The Strategic Role of CDMOs in Pharma Manufacturing

CDMOs in pharmaceutical manufacturing are much more than outsourced production. They provide the process expertise, manufacturing capacity, technology, and operational infrastructure needed to turn complex biologics into scalable products.

Image

Why CDMOs Matter So Much in Pharmaceutical Manufacturing

The rise of biologics has changed how pharmaceutical companies organise manufacturing.

Unlike many small-molecule medicines, biologics depend on complex biological systems, specialised facilities, sophisticated process controls, and highly skilled technical teams.

This shift can be seen as a horizontal division of pharmaceutical activities. Drug discovery and development can remain with pharmaceutical or biotechnology companies, while contract development manufacturing organization (CDMOs) take responsibility for process development and manufacturing.

This model addresses a practical problem. Building and maintaining internal manufacturing capability requires substantial capital, specialist expertise, and ongoing investment.

For smaller biotechnology companies, those requirements can create a significant barrier to advancing promising candidates.

CDMOs provide the workable alternative. Their facilities can support multiple customers, allowing manufacturing assets, process expertise, and specialist capabilities to be shared across programmes.

The value is so much more than capacity. A strong CDMO can help a sponsor:

• Develop and optimise manufacturing processes
• Scale production as programmes advance
• Access specialised facilities and equipment
• Transfer processes into GMP manufacturing
• Reduce the need for upfront infrastructure investment
• Apply established manufacturing expertise to complex biologics

The model also allows pharmaceutical companies to focus internal resources on activities where they have the strongest competitive advantage.

However, outsourcing does not transfer regulatory responsibility away from the sponsor. Manufacturing accountability still requires strong oversight, defined responsibilities, and effective quality systems.

The U.S. Food and Drug Administration (FDA) guidance on contract manufacturing arrangements recommends clear quality agreements that define the manufacturing responsibilities of each party.

View interview How AI Is Opening New Opportunities in Fertility Care for Pharma

How AI Is Opening New Opportunities in Fertility Care for Pharma

"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.

Image

Why Is the Semiconductor Foundry Model Important for Pharma?

One of the most interesting aspects for pharma development is the relationship between CDMOs and semiconductor foundries.

The semiconductor industry developed a model in which specialised foundries manufacture products for companies that focus on chip design. This allowed design-led companies to innovate without building their own manufacturing infrastructure.

Biopharmaceutical CDMOs can develop a similar position, and there are three core success factors:

1. Advanced and reliable production technology
2. Sufficient manufacturing capacity when customers need it
3. Services that match individual customer requirements

However, manufacturing capacity alone does not create a strategically valuable CDMO.

A facility can have available bioreactors, cleanrooms, and production slots, but sponsors also need process knowledge, reliable technology transfer, consistent quality, and the ability to scale.

This changes how CDMO selection should be approached.

A procurement-led assessment that focuses mainly on price and available capacity can miss the capabilities that determine long-term programme performance.

Instead, sponsors should examine whether a CDMO has the technical depth to solve manufacturing problems as programmes evolve.

That becomes particularly important when a molecule moves from development into larger-scale production because a process that works at laboratory scale does not automatically translate into a robust commercial manufacturing process.

Is Manufacturing Technology the Differentiator for CDMOs?

Technology development is at the centre of long-term CDMO competitiveness.

This is particularly clear in monoclonal antibody manufacturing. The manufacturing platform for antibodies has become relatively standardised, covering cell-line development, upstream culture, downstream purification, viral inactivation, and final processing.

That manufacturing standardisation has helped make antibody production increasingly suitable for outsourcing.

But, it also creates a new challenge.

If many organisations can provide broadly similar manufacturing services, technology becomes the differentiator.

There have been significant developments in relation to Chinese hamster ovary cell platforms, continuous culture, process optimisation, and continuous chromatography that have stood out. These approaches can improve productivity, process efficiency, and manufacturing economics.

Continuous manufacturing is particularly relevant. It can support smaller production footprints and more consistent process conditions, although the transition from established batch systems remains technically and economically challenging.

There is also the growing role of process analytical technology and digital process management to consider.

This has big implications for technical operations teams who must evaluate whether the CDMO partner can improve the manufacturing process over its lifecycle.

That means evaluating capabilities such as:

• Process development and optimisation
• Cell-line engineering
• Scale-up and technology transfer
• Process analytical technology
• Continuous manufacturing
• Digital process monitoring
• Analytical development
• Manufacturing data management

This aligns with the wider digitalisation of pharmaceutical manufacturing, and Pharmatica’s analysis of data integrity and ALCOA highlights why reliable manufacturing data is becoming an operational asset rather than simply a compliance requirement.

Image

Pharma Quality Cannot Be Outsourced

The growth of CDMOs creates a second strategic issue: outsourcing manufacturing does not mean outsourcing quality ownership.

FDA CDMO guidance states that pharmaceutical companies using contract manufacturers should establish clear responsibilities through quality agreements.

These agreements should define activities, specifications, communication mechanisms, and the respective quality responsibilities of the parties. 

International Council for Harmonisation (ICH Q7) also expects companies to assess contractors for GMP compliance and maintain formal agreements covering responsibilities, quality measures, auditing, subcontracting, and change management.

This makes CDMO governance a core capability. A robust relationship needs more than a signed contract. It needs mechanisms for managing:

Quality → Data → Change → Capacity → Risk → Performance

That’s more complex as programmes move from clinical development towards commercial supply.

Changes to equipment, processes, analytical methods, raw materials, or manufacturing sites can have regulatory and product-quality implications. Sponsors therefore need sufficient visibility into the CDMO’s quality system and change-control processes.

The principle also applies to emerging modalities. In antibody development, CDMOs are increasingly contributing beyond manufacturing, including to areas such as candidate development and structural optimisation. 

The CDMO relationship is therefore becoming more integrated. That creates opportunities, but it also increases the importance of governance.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Image

CDMO’s Are the Vital for Next-generation Pharma Manufacturing

The role of the CDMO is changing from capacity provider to technical partner.

The future strength of biopharmaceutical CDMOs will depend on continued investment in manufacturing technology and the ability to develop distinctive capabilities. 

That insight remains relevant as biologics become more complex and manufacturing requirements become more specialised, and it makes the key question more than which CDMO has capacity?

Instead, it’s which partner can provide the technology, manufacturing expertise, quality systems, data, and scalability required across the product lifecycle?

The answer should influence CDMO selection, governance, technology-transfer planning, and long-term Technical Operations strategy.

Pharmatica’s Chain Reaction perspective is built around this connection between manufacturing, technology, data, quality, and resilience. Our Insights focus on how operational capabilities translate into measurable outcomes across the pharmaceutical lifecycle.

Pharmatica: Insight. Connection. Impact.